Clinical Trial Update: Safety and PK Study of NOV-205 to Treat Chronic HCV Who Fail Standard Therapy [Phase 1]

View source ↗

Summary

This release covers a Phase 1 safety and pharmacokinetics study of NOV-205 in chronic hepatitis C patients who failed standard therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• NOV-205

Snippet

Sponsor: Cellectar Biosciences, Inc. | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED